ClinicalTrials.Veeva

Menu

Polaris Oncology Survivor Transition (POST) System

P

Polaris Health Directions

Status and phase

Completed
Phase 2

Conditions

Cancer

Treatments

Behavioral: POST Intervention
Behavioral: POST Treatment as Usual

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02637349
2R42CA174048-03

Details and patient eligibility

About

The POST's public health impact is likely to be substantial because it will improve cancer survivorship planning, which is currently an important deficiency in cancer care recognized by the Institute of Medicine and the American College of Surgeons.

The POST may have many potential benefits for patients such as:

  1. improved long-term health outcomes;
  2. improved psychosocial outcomes and quality of life;
  3. smoother transitions back into old and new life roles; and
  4. improved continuity and coordination of care between providers.

Most importantly, the POST's influence may reach beyond the patients it directly serves as it could help scientists and health care providers understand the potential benefits of cancer survivorship planning and how to best design and implement survivorship planning when patients are ending treatment for cancer.

Full description

By January 2015, oncology care providers will be expected to craft Survivorship Care Plans (SCPs) for all individuals ending active treatment for cancer; however, there is a lack of systematic study of the impact survivorship planning has on patients, providers, or healthcare systems. The Polaris Oncology Survivorship Transition (POST) program is a web-based system that incorporates recommendations from the Institute of Medicine (IOM) and American College of Surgeons (ACS) to assist with cancer survivorship planning. It is a patient-centered approach that integrates input from both the treating oncology team and the patient. Phase 1 built and iteratively modified (N=25) the POST system and Phase 2 will test whether the SCPs impact patient and provider outcomes using a single blind, randomized controlled trial (RCT). Breast cancer patients (n=230) transitioning out of active treatment will be recruited and randomly assigned to receive Treatment as Usual (n=115) or the POST (n=115). All participants will be assessed at 1, 3, and 6 months by a research assistant blind to baseline status and group assignment. Primary outcomes will include quality of life, mechanisms of action such as confidence in entering survivorship, and other outcomes such as (1) depression and anxiety, (2) adherence to medical and behavioral health recommendations, (3) health care utilization, and (4) patient and provider satisfaction with the POST system.The POST will innovate the clinical setting through being the first system to produce computer generated tailored survivorship plans fully reflecting IOM recommendations and the new ACS 2015 requirements; incorporating information from both the oncology provider and the patient; featuring readily available "plug in" for two-way electronic health record integration; providing dynamic, electronic referrals for specialized support services; and facilitating care coordination between the oncologist and PCP. This study's impact will be significant. If hypotheses are confirmed, clear scientific evidence will exist for supporting survivorship care planning into oncology clinical practice. If hypotheses are disconfirmed, important lessons will guide future directions for care planning, including whether failure to affect outcomes was due to failure to impact several hypothesized mechanisms of action.

Enrollment

200 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 18 years or older
  • Confirmed diagnosis of breast cancer (not metastatic)
  • A final active treatment appointment scheduled with oncology team
  • Able to read or understand English at a 6th grade level

Exclusion criteria

  • Altered mental status (e.g., psychosis, delirium, disorientation)
  • Visual problems preventing them from reading the assessment and reports
  • Severe illness that would preclude conversation or interface with a computer (e.g.,persistent nausea/vomiting, severe pain)
  • Unable to read or understand English at a 6th grade level
  • Characteristics that would prevent adequate follow-up (e.g., lack of a telephone)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

POST SCP
Experimental group
Description:
Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
Treatment:
Behavioral: POST Intervention
POST TAU
Active Comparator group
Description:
Patient receives treatment as usual (TAU) after active treatment ends.
Treatment:
Behavioral: POST Treatment as Usual

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems